Avid Bioservices Inc (CDMO)

[BioBS2012]

Needs some potential catalyst.

Below is the list compiled by Dia.... that you might find useful.

Catalysts?TIME forANOTHER POTENTIAL NEWS LIST forNEWBIES UPDATE (back by popular demand)

There is a lot of news to come.....and a lot of new investors.
Which of the following might these releases concern? For any detailed answers look at the great introduction section compiled by CjGaddy!

1. Bavi Oncology partnership or partnerships.

2. Liver cancer IST results. The interim results released at a scientific conference in March showed 34 of 38 Phase II were enrolled. Good safety results ....one patient on trial for 18 months. More efficacy results to come.

3. Liver cancer partnership

4. Cotara partnership announcement

5. Breast cancer IST results published in an academic journal.

6. Breast cancer advancing in clinic

7. Ambulance Chaser Lawsuit ended? Cannot believe how this can be dragged out. The old maxim is true! "Justice delayed is justice denied."

8. CSM settlement

9. Betabodies preclinical

10. Bavi plus other immunotherapies preclinical results...we already have some very interesting Bavi plus Yervoy preclinical results. But there is more to come.In recent presentations PPHM has mentioned 12 or more potential Bavi/immunotherapy combinations. That does not rule out the potential of a cocktail of several of these being used together. So far we have only seen some results from the Bavi/Yervoy preclinical combination. Obviously there is a lot more news to come.

a.anti-CTLA-4 (Yervoy)
b.anti-PD-1
c.anti-PD-L1
d.anti-TGF-b
e.anti-IL-10
f.GM-CSF
g.IFN-a
h.IL-2
i.Provenge
j.other vaccines
k.appropriate TKI
l.radiation plus androgen deprivation
m.anti-CD47 and anti-CD54. Preliminary Abstract presented at AAI May 2013. More to come?
n.IDO pathway inhibitors.

11. Bavi plus Yervoy clinical trial is underway !!!!!!! YES

12. Dr. Brekken announcements(publications,editorials,presentations). An article appeared in a prestigious EU publication in December. Immunology talk given on May 28. More to come.

13. Another Govt. deal for viruses? HIV presentation in March raises this issue..

14. Breakthrough, Accelerated Approval or Priority Review announcements?

15. Imaging data update

16. New analyst coverage?

17. Institutional ownership increase?

18. Fast track for second line NSCLC announced in January. AA and PR could follow.

19. Sale of Series E Preferred Convertible shares has now increased the companies cash to some $80 million. More financing news to come. How is this related to trials and/or partnerships?

20. A really huge catalyst would be an early approval of Bavi in the second line NSCLC indication because a DMC decision based on exceptional results, or early approval based on the first or second event based look-ins!

Coming Events.

Jul31-Aug2: "15th Annual Intl. Lung Cancer Congress (ILCC)" tinyurl.com/k8ypsp
…Speaker: Jeff Hutchins (PhD, PPHM’s VP/PreClin.Res)

Aug11: CHI’s 2nd Annual Immunomodulatory Therapeutic Antibodies for Cancer Conf., Boston http://tinyurl.com/lsenjds
…12pm, Jeff Hutchins, PhD (PPHM’s VP/PreClinDEV), “PS-Targeting Antibodies Enhance Activity of Immune Checkpoint Inhibitors by Repolarizing Immunosuppressive Immune Cells Populating the Tumor Microenvironment”

Sep4-6, “ASCO’s 2014 Breast Cancer Symposium”, SanFran http://tinyurl.com/om9e3es
…PPHM Exhibiting/Booth#10 (14 corp. a/o 6-30-14, incl. Pfizer Genentech Novartis MedImmune) – exhibitors http://tinyurl.com/nbxwytz

~Sep8: FY'15/Q1 (q/e 7-31-14) Financials & Conf. Call http://ir.peregrineinc.com/events.cfm

Sept26-30 2014: “ESMO 2014: European Society for Medical Oncology”, Madrid
“The theme for ESMO 2014 is ‘Precision Medicine in Cancer Care.’ Whether you are a medical or surgical oncologist, radiotherapist, immunologist, or pathologist, practicing precision medicine means we are all working towards a common goal - improved patient outcomes. This is the ultimate goal of ESMO 2014.”
http://www.esmo.org/Conferences/ESMO-2014-Congress
http://www.esmo.org/Conferences/ESMO-2014-Congress/Industry-Participation
Industry Partner: Peregrine Pharmaceuticals